Literature DB >> 1582595

Circulating von Willebrand factor in inflammatory bowel disease.

T R Stevens1, J P James, N J Simmonds, D A McCarthy, I F Laurenson, P J Maddison, D S Rampton.   

Abstract

Raised circulating von Willebrand factor is a recognised marker of vascular injury. To evaluate the role of vascular injury in the pathogenesis of inflammatory bowel disease, serum von Willebrand factor in Crohn's disease, ulcerative colitis, confirmed bacterial diarrhoea, and healthy subjects was measured. von Willebrand factor values were raised in 9/14 patients (p = 0.007) with active Crohn's disease, 15/28 (p = 0.0004) with inactive Crohn's disease, 16/23 (p = 0.0003) with active ulcerative colitis, 9/27 (p = 0.04) with inactive ulcerative colitis, and 15/17 (p = 0.0001) patients with bacterial diarrhoea. Serum von Willebrand factor was unrelated to disease activity in Crohn's disease but was significantly raised in active (p = 0.02) compared with inactive ulcerative colitis. In contrast to controls, the detection of von Willebrand factor from inflammatory bowel disease sera and that from fractured endothelial cells was significantly inhibited by the reducing agent, dithiothreitol, suggesting the presence of an additional dithiothreitol sensitive form of the molecule derived from injured endothelial cells in inflammatory bowel disease. That serum von Willebrand factor is raised in quiescent as well as active Crohn's disease is compatible with the proposal that vascular injury is a fundamental abnormality in this disorder. The raised von Willebrand factor values in active inflammatory bowel disease and bacterial diarrhoea could be caused by either vascular injury, occurring secondary to bowel inflammation, or to an acute phase response resulting from endothelial cell stimulation by mediators released during the inflammatory process. Raised circulating von Willebrand factor could contribute to the increased risk of thrombosis associated with active inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1582595      PMCID: PMC1374067          DOI: 10.1136/gut.33.4.502

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  17 in total

1.  VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS.

Authors:  J H BARON; A M CONNELL; J E LENNARD-JONES
Journal:  Br Med J       Date:  1964-01-11

Review 2.  Molecular and cellular biology of von Willebrand factor.

Authors:  R I Handin; D D Wagner
Journal:  Prog Hemost Thromb       Date:  1989

3.  Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction.

Authors:  A J Wakefield; A M Sawyerr; A P Dhillon; R M Pittilo; P M Rowles; A A Lewis; R E Pounder
Journal:  Lancet       Date:  1989-11-04       Impact factor: 79.321

4.  Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface.

Authors:  R Hattori; K K Hamilton; R P McEver; P J Sims
Journal:  J Biol Chem       Date:  1989-05-25       Impact factor: 5.157

5.  Thrombosis in inflammatory bowel disease.

Authors:  K P Koenigs; P McPhedran; H M Spiro
Journal:  J Clin Gastroenterol       Date:  1987-12       Impact factor: 3.062

6.  On the aetiology of ulcerative colitis. A vascular hypothesis.

Authors:  R A Fairburn
Journal:  Lancet       Date:  1973-03-31       Impact factor: 79.321

7.  Experimental endotoxemia increases plasma von Willebrand factor antigen concentrations in dogs with and without free-radical scavenger therapy.

Authors:  M J Novotny; M A Turrentine; G S Johnson; H R Adams
Journal:  Circ Shock       Date:  1987

8.  Deposits of terminal complement complex (TCC) in muscularis mucosae and submucosal vessels in ulcerative colitis and Crohn's disease of the colon.

Authors:  T S Halstensen; T E Mollnes; O Fausa; P Brandtzaeg
Journal:  Gut       Date:  1989-03       Impact factor: 23.059

9.  Persistent complement activation in submucosal blood vessels of active inflammatory bowel disease: immunohistochemical evidence.

Authors:  T S Halstensen; T E Mollnes; P Brandtzaeg
Journal:  Gastroenterology       Date:  1989-07       Impact factor: 22.682

10.  Factor VIII von Willebrand protein in haemolytic uraemic syndrome and systemic vasculitides.

Authors:  P E Rose; G S Struthers; M Robertson; J Kavi; I Chant; C M Taylor
Journal:  Lancet       Date:  1990-03-03       Impact factor: 79.321

View more
  19 in total

1.  Hyperhomocysteinemia in Greek patients with inflammatory bowel disease.

Authors:  I E Koutroubakis; E Dilaveraki; I G Vlachonikolis; E Vardas; G Vrentzos; E Ganotakis; I A Mouzas; A Gravanis; D Emmanouel; E A Kouroumalis
Journal:  Dig Dis Sci       Date:  2000-12       Impact factor: 3.199

2.  Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation.

Authors:  Petros Zezos; Georgia Papaioannou; Nikolaos Nikolaidis; Themistoclis Vasiliadis; Olga Giouleme; Nikolaos Evgenidis
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

3.  Budd-Chiari syndrome in a patient with ulcerative colitis and no inherited coagulopathy.

Authors:  Sunil Dacha; Manjari Devidi; Evan Osmundson
Journal:  World J Hepatol       Date:  2011-06-27

4.  Anti-endothelial cell antibodies in inflammatory bowel disease.

Authors:  T R Stevens; S L Harley; J S Groom; G Cambridge; B Leaker; D R Blake; D S Rampton
Journal:  Dig Dis Sci       Date:  1993-03       Impact factor: 3.199

5.  von Willebrand factor in upper gastrointestinal tract inflammation.

Authors:  A D Blann
Journal:  Gut       Date:  1993-02       Impact factor: 23.059

6.  Adhesion molecules in inflammatory bowel disease.

Authors:  S C Jones; R E Banks; A Haidar; A J Gearing; I K Hemingway; S H Ibbotson; M F Dixon; A T Axon
Journal:  Gut       Date:  1995-05       Impact factor: 23.059

7.  Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease.

Authors:  I E Koutroubakis; E Petinaki; E Anagnostopoulou; H Kritikos; I A Mouzas; E A Kouroumalis; O N Manousos
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

Review 8.  Venous thrombosis and prothrombotic factors in inflammatory bowel disease.

Authors:  Fernando Magro; João-Bruno Soares; Dália Fernandes
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

9.  Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease.

Authors:  J C Souto; E Martínez; M Roca; J Mateo; J Pujol; D González; J Fontcuberta
Journal:  Dig Dis Sci       Date:  1995-09       Impact factor: 3.199

10.  High nitric oxide synthase activity in endothelial cells in ulcerative colitis.

Authors:  E Iwashita; T Miyahara; K Hino; T Tokunaga; H Wakisaka; Y Sawazaki
Journal:  J Gastroenterol       Date:  1995-08       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.